ION904

Ionis Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	ION904
Sponsor	Ionis Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension (PHASE2)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ION904 CI brief — competitive landscape report
ION904 updates RSS · CI watch RSS
Ionis Pharmaceuticals, Inc. portfolio CI